Phase 2 Depression and Anxiety Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been formally diagnosed with Generalized Anxiety Disorder (GAD), confirmed through a structured medical interview called the MINI.
- People who are currently taking an antidepressant medication for GAD as specified by the trial, have been taking it at the recommended dose for at least 8 weeks, and their anxiety has not improved enough — confirmed through scores on two standard anxiety rating scales completed at the start of the trial.
Who may not be able to join:
- People whose score on a standard depression rating scale (called the MADRS) is 20 or higher, indicating significant depression symptoms.
- People who have been newly diagnosed with major depression, or whose depression has significantly worsened, within the past 6 months.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants with Adverse Events (AEs); Change from Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.